pharmaphorum4d
Rova-T: the story of AbbVie’s multi-billion dollar failure
Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...
Business Insider India8y
Here's the cancer data that led AbbVie to make the second-largest acquisition in the history of venture capital
In April, Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was acquired by AbbVie for $5.8 billion in cash and stock in a deal that in ...
Business Insider India8y
A startup you've never heard just got acquired by a major pharmaceutical company for $5.8 billion
A $5 billion startup called Stemcentrx, with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was just acquired by AbbVie for $5.8 billion. Stemcentrx is in ...
pharmaphorum27d
Rova-T: the story of AbbVie’s multi-billion dollar failure
Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...